Journal
JOURNAL OF CLINICAL NEUROSCIENCE
Volume 53, Issue -, Pages 263-264Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jocn.2018.04.043
Keywords
Cerebellar ataxia; Cerebrotendinous Xanthomatosis; Riluzole; Chenodeoxycholic Acid
Categories
Ask authors/readers for more resources
Cerebrotendinous Xanthomatosis (CTX) is a rare genetic disorder due to mutations in the CYP27A1 gene resulting in both systemic and neurologic manifestations from accumulation and deposition of cholestanol in tissues. Chenodeoxycholic Acid (CDCA) is the standard medical therapy, resulting in decreased cholestanol synthesis, however, neurologic improvement is typically not seen. Riluzole may have a symptomatic benefit in ataxia from a presumed protective effect on Purkinje cells. To date, there are no reports of symptomatic improvement in CTX related ataxia following treatment with Riluzole. We report the case of a 45 year old woman diagnosed with CTX-related cerebellar ataxia. Therapy with CDCA and Riluzole resulted in quantifiable improvement on the Scale for the Assessment and Rating of Ataxia (SARA). Thus, in addition to the standard therapy with CDCA, the addition of Riluzole may have some therapeutic benefits for ataxia caused by CTX. Further controlled studies are needed. (C) 2018 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available